TXG logo

10x Genomics, Inc.

TXG
Healthcare|Biotechnology|US
$59.28
+1.22 (+2.10%)
Tangible Book / Share
$5.91
Cash / Share
$4.40

About

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

Stock Price

+356.0%(1Y)
1M
-23.3%
3M
+13.9%
6M
+174.4%
YTD
+263.5%
1Y
+247.1%
3Y
+56.3%
5Y
-66.0%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$7.13B
Employees1,178 (-10% YoY)
CEOSerge Saxonov
IPO DateSep 12, 2019
Beta2.03
52-Week Range$15.12 – $102.81
Avg Volume3,330,410
ExchangeNASDAQ

Ownership

Float96.6%
Shares Outstanding120.2M

Recent Insider Trades

Satpathy AnsumanOTHER
Oct 28, 20260 shares
Gilliam Joseph EOTHER
Oct 28, 20260 shares
SULIMAN SHEHNAAZSELL
Sep 22, 2026292 shares @ $78.20
SULIMAN SHEHNAAZSELL
Sep 22, 2026614 shares @ $79.51
SULIMAN SHEHNAAZSELL
Sep 22, 20261,325 shares @ $80.82

Peers

AAgilent Technologies, Inc.
$49.28B
BIOBio-Rad Laboratories, Inc.
$10.25B
GNNSFGenscript Biotech Corporation
$10.12B
ILMNIllumina, Inc.
$32.23B
LABStandard BioTools Inc.
$251.0M
QGENQiagen N.V.
$10.39B
RVTYRevvity, Inc.
$17.31B
TECHBio-Techne Corporation
$11.43B
Data last updated: Nov 9, 2026, 04:38 AM